These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1462 related items for PubMed ID: 20927777

  • 1. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Spaulding A, Rutherford GW, Siegfried N.
    Cochrane Database Syst Rev; 2010 Oct 06; (10):CD008740. PubMed ID: 20927777
    [Abstract] [Full Text] [Related]

  • 2. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw LC, Irlam JH, Spaulding A, Rutherford GW, Siegfried N.
    Cochrane Database Syst Rev; 2010 Dec 08; (12):CD004246. PubMed ID: 21154355
    [Abstract] [Full Text] [Related]

  • 3. Stavudine or zidovudine in three-drug combination therapy for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Spaulding A, Rutherford GW, Siegfried N.
    Cochrane Database Syst Rev; 2010 Aug 04; (8):CD008651. PubMed ID: 20687097
    [Abstract] [Full Text] [Related]

  • 4. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw L, Mursleen S, Irlam JH, Spaulding AB, Rutherford GW, Siegfried N.
    Cochrane Database Syst Rev; 2016 Dec 10; 12(12):CD004246. PubMed ID: 27943261
    [Abstract] [Full Text] [Related]

  • 5. WITHDRAWN. Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV.
    Omeje I, Okwundu CI.
    Cochrane Database Syst Rev; 2012 Feb 15; (2):CD007276. PubMed ID: 22336829
    [Abstract] [Full Text] [Related]

  • 6. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O.
    Cochrane Database Syst Rev; 2013 Jun 05; 2013(6):CD008270. PubMed ID: 23740608
    [Abstract] [Full Text] [Related]

  • 7. Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?
    Labhardt ND, Bader J, Lejone TI, Ringera I, Puga D, Glass TR, Klimkait T.
    Trop Med Int Health; 2015 Jul 05; 20(7):914-8. PubMed ID: 25782332
    [Abstract] [Full Text] [Related]

  • 8. Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy.
    Humphreys EH, Chang LW, Harris J.
    Cochrane Database Syst Rev; 2010 Jun 16; (6):CD006517. PubMed ID: 20556768
    [Abstract] [Full Text] [Related]

  • 9. WITHDRAWN: Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV.
    Omeje I, Okwundu CI.
    Cochrane Database Syst Rev; 2012 May 16; 2012(5):CD007276. PubMed ID: 22592718
    [Abstract] [Full Text] [Related]

  • 10. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
    Pozniak AL, Gallant JE, DeJesus E, Arribas JR, Gazzard B, Campo RE, Chen SS, McColl D, Enejosa J, Toole JJ, Cheng AK.
    J Acquir Immune Defic Syndr; 2006 Dec 15; 43(5):535-40. PubMed ID: 17057609
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R, Calza L.
    AIDS Patient Care STDS; 2008 Apr 15; 22(4):279-90. PubMed ID: 18290748
    [Abstract] [Full Text] [Related]

  • 16. Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts.
    Ouattara E, Danel C, Moh R, Gabillard D, Peytavin G, Konan R, Carrou JL, Bohoussou F, Eholie SP, Anglaret X.
    J Int AIDS Soc; 2013 Apr 30; 16(1):18059. PubMed ID: 23639243
    [Abstract] [Full Text] [Related]

  • 17. Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study.
    Blanco JR, Caro-Murillo AM, Castaño MA, Olalla J, Domingo P, Arazo P, Gómez-Sirvent JL, Riera M, Pulido F, Vera F, Romero-Palacios A, Aguirrebengoa K, Portilla J, Ferrer P, Pedrol E.
    HIV Clin Trials; 2013 Apr 30; 14(5):204-15. PubMed ID: 24144897
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.
    Behrens G, Rijnders B, Nelson M, Orkin C, Cohen C, Mills A, Elion RA, Vanveggel S, Stevens M, Rimsky L, Thorpe D, Bosse M, White K, Zhong L, DeMorin J, Chuck SK.
    AIDS Patient Care STDS; 2014 Apr 30; 28(4):168-75. PubMed ID: 24660840
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 74.